NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

NATCO PHARMA LTD.

NSE : NATCOPHARMBSE : 524816ISIN CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse : Natco
BSE999.45-22.6 (-2.21 %)
PREV CLOSE ( ) 1022.05
OPEN PRICE ( ) 1029.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 9931
TODAY'S LOW / HIGH ( )995.80 1029.75
52 WK LOW / HIGH ( )563 1107.85
NSE998.60-24.2 (-2.37 %)
PREV CLOSE( ) 1022.80
OPEN PRICE ( ) 1028.00
BID PRICE (QTY) 998.60 (294)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 367850
TODAY'S LOW / HIGH( ) 995.80 1031.00
52 WK LOW / HIGH ( )563 1108.35
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 19-09 1981
Management Info
G S Murthy - Chairman V C Nannapaneni - Managing Director
Registered Office

Address Natco House,Road No 2,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040-23547532

Email investors@natcopharma.co.in / dasaradhi@natcopharma.co.in

Website www.natcopharma.co.in

Registrars Details
Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
 Listing : BSE, NSE, MCX
NEWS
23Apr NATCO Pharma informs about disclosure
Further to its earlier intimation dated November 2, 2023 about the succe..
18Apr NATCO Pharma informs about press release
NATCO Pharma has informed that it enclosed the Press Release and disclos..
09Apr NATCO Pharma informs about updates
NATCO Pharma has informed about update on USFDA inspection at Natco’s ma..
09Apr Natco Pharma gets warning letter from
Natco Pharma has received a warning letter from the US health regulator..
09Apr Update On USFDA Inspection At Natco'S
Update on USFDA inspection at NATCO''s Manufacturing facility in Kothur,..
MORE
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit19206371
Gross Profit 2236 7707
Operating Profit 26789302
Net Sales 625323510
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
NGL Fine-Chem (BSE)
 2621.00 (5.75%)
M.Cap (Rs. in Cr)1619.26
Glaxosmithkline Phar (BSE)
 2079.80 (7.06%)
M.Cap (Rs. in Cr)35233.07
TTK Healthcare (BSE)
 1591.35 (5.77%)
M.Cap (Rs. in Cr)2248.63
Cipla (BSE)
 1398.80 (3.79%)
M.Cap (Rs. in Cr)112938.41
Torrent Pharma (BSE)
 2685.00 (1.85%)
M.Cap (Rs. in Cr)90872.60
MORE
Shareholding Pattern
PROMOTERS 49.71%
NON-INSTITUTION 24.46%
FI/BANKS/INSURANCE 5.58%
MUTUAL FUNDS/UTI 4.08%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| REFUND & CANCELLATION POLICY| DISCLAIMER| DISCLOSURE| KMP DETAILS | CDSL e-Voting | SEBI| FMC| NSE| BSE| MCX | SCORES
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
Assamese Bengali Gujrati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
SMART ODR Portal
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.